International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

被引：121

作者：

Lokhorst, Henk

Einsele, Hermann

Vesole, David

Bruno, Benedetto

Miguel, Jesus San

Perez-Simon, Jose A.

Kroger, Nicolaus

Moreau, Philippe

Gahrton, Gosta

Gasparetto, Cristina

Giralt, Sergio

Bensinger, William

机构：

[1] Univ Utrecht Hosp, Utrecht, Netherlands

[2] Univ Hosp Wuerzburg, Wurzburg, Germany

[3] Univ Hosp Hamburg Eppendorf, Hamburg, Germany

[4] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Univ Turin, Giovanni Battista Hosp, Turin, Italy

[6] Univ Hosp Salamanca, Salamanca, Spain

[7] Ctr Hosp Univ Hotel Dieu, Nantes, France

[8] Karolinska Univ Hosp, Karolinska Inst, Stockholm, Sweden

[9] Duke Univ Hosp, Durham, NC USA

[10] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Univ Washington, Seattle, WA 98195 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 29期

关键词：

VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSIONS; IN-SITU HYBRIDIZATION; TANDEM AUTOLOGOUS TRANSPLANTATION; MINOR HISTOCOMPATIBILITY ANTIGENS; COOPERATIVE-ONCOLOGY-GROUP; NEWLY-DIAGNOSED MYELOMA; HIGH-DOSE CHEMOTHERAPY; RELAPSE-FREE SURVIVAL;

D O I：

10.1200/JCO.2010.29.7929

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials. J Clin Oncol 28:4521-4530. (C) 2010 by American Society of Clinical Oncology

引用

页码：4521 / 4530

页数：10

共 107 条

[41] Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients [J].

Galimberti, S ;

Morabito, F ;

Guerrini, F ;

Palumbo, GA ;

Azzará, A ;

Martino, M ;

Benedetti, E ;

Di Raimondo, F ;

Petrini, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (03) :405-412

[42] Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma [J].

Garban, F ;

Attal, M ;

Michallet, M ;

Hulin, C ;

Bourhis, JH ;

Yakoub-Agha, I ;

Lamy, T ;

Marit, G ;

Maloisel, F ;

Berthou, C ;

Dib, M ;

Caillot, D ;

dePrijck, B ;

Ketterer, N ;

Harousseau, JL ;

Sotto, JJ ;

Moreau, P .

BLOOD, 2006, 107 (09) :3474-3480

[43] Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy [J].

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A ;

Greipp, PR ;

Litzow, MR ;

Henderson, KJ ;

Van Wier, SA ;

Ahmann, GJ ;

Fonseca, R .

BLOOD, 2005, 106 (08) :2837-2840

[44] Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma [J].

Gerull, S ;

Goerner, M ;

Benner, A ;

Hegenbart, U ;

Klein, U ;

Schaefer, H ;

Goldschmidt, H ;

Ho, AD .

BONE MARROW TRANSPLANTATION, 2005, 36 (11) :963-969

[45] Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue [J].

Giralt, S ;

Weber, D ;

Colome, M ;

Dimopoulos, M ;

Mehra, R ;

VanBesien, K ;

Gajewski, J ;

Andersson, B ;

Khouri, I ;

Przepiorka, D ;

vonWolff, B ;

Delasalle, K ;

Korbling, M ;

Seong, D ;

Alexanian, R ;

Champlin, R .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :667-673

[46] GRAFT-VERSUS-HOST DISEASE IN CYCLOSPORIN A-TREATED RATS AFTER SYNGENEIC AND AUTOLOGOUS BONE-MARROW RECONSTITUTION [J].

GLAZIER, A ;

TUTSCHKA, PJ ;

FARMER, ER ;

SANTOS, GW .

JOURNAL OF EXPERIMENTAL MEDICINE, 1983, 158 (01) :1-8

[47] Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM) [J].

Goldschmidt, Hartmut ;

Lokhorst, Henk M. ;

Bertsch, Uta ;

Van der Holt, Bronno ;

el Jarari, Laila ;

Salwender, Hans-Juergen ;

Zweegman, Sonja ;

Vellenga, Edo ;

Schubert, Joerg ;

Blau, Igor W. ;

Jie, Asiong ;

Beverloo, Bema ;

Hose, Dirk ;

Van de Velde, Helgi ;

Schaafsma, Martyn Ronald ;

Kersten, Marie Jose ;

Delforge, Michel ;

de Weerdt, Okke ;

Van der Griend, Rene ;

Wijermans, Pierre ;

Martin, Hans ;

Scheid, Christof ;

Haenel, Mathias ;

Schmidt-Wolf, Ingo G. H. ;

Sonneveld, Pieter .

BLOOD, 2008, 112 (11) :1190-1190

[48] Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia:: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals [J].

Gutierrez, N. C. ;

Ocio, E. M. ;

Rivas, J. de las ;

Maiso, P. ;

Delgado, M. ;

Ferminan, E. ;

Arcos, M. J. ;

Sanchez, M. L. ;

Hernandez, J. M. ;

Miguel, J. F. San .

LEUKEMIA, 2007, 21 (03) :541-549

[49] Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region [J].

Heemskerk, MHM ;

Hoogeboom, M ;

de Paus, RA ;

Kester, MGD ;

van der Hoorn, MAWG ;

Goulmy, E ;

Willemze, R ;

Falkenburg, JHF .

BLOOD, 2003, 102 (10) :3530-3540

[50] Susceptibility of malignant plasma cells to HA-1H specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect [J].

Holloway, PA ;

Kaldenhoven, N ;

van Dijk, M ;

Bloem, AC ;

de Lau, W ;

van der Zee, R ;

Kircher-Eibl, B ;

Mutis, T ;

Lokhorst, HM .

LEUKEMIA, 2004, 18 (09) :1543-1545

← 1 2 3 4 5 6 7 8 9 10 →